Equity
QS Invest has made a profit in every financial year since 2022.
QS Invest has made a profit in every financial year since 2022.
The micro format states no turnover.
Subsidiary with negative equity. QS Supplements · loss of €69,411 in 2025.
The dashed line is the sector median: 0.6% across 40,273 companies (NACE 47, micro).
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 61% of them on solvency, 32% on liquidity, 27% on profitability and 40% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
In July 2024, 10,904 companies had the same profile as QS Invest has now. Each dot stands for 28 companies, two years later.
That fits the bankruptcy probability of QS Invest itself: 0.6% within 12 months.
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 10,904 companies, not a prediction for QS Invest. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Liquidity is ample, with a current ratio of 1.55 (1.43 in 2024), above the usual 1.5. Short-term debt is 52.4% and cash 9.1% of total assets. However, 53.2% of the assets are financed with debt and provisions.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The company filed its last 4 accounts on average 48 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Shares in 1 company, QS Supplements
Board & ownership| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| QS Invest Nazareth-De Pinte | €279,436 | €15,269 | 46.8% | - |
| MD MEDIC Ghent | €369,386 | €24,935 | 79.4% | - |
| ZorgVrij Ravels | €253,142 | €18,847 | 34.4% | - |
| NMH CONCEPT Braine-l'Alleud | €315,558 | €25,697 | 62.2% | - |
| Medi-Rent Zele | €156,724 | €19,099 | 82.2% | - |
| SOL SCIENTIFICS Ghent | €426,554 | €21,761 | -8.8% | - |
| MEDISOINS & MEDIZORG METTEWIE Molenbeek-Saint-Jean | €146,912 | €14,368 | -94.8% | - |
These companies have the same main activity as QS Invest: retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741). They are comparable in size and age: total assets between €147,000 and €427,000, founded between 2016 and 2020.
QS Invest files the micro format. That format states no turnover. The gross margin fell from €61,650 in 2022 to €15,269 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.